AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

EyePoint Pharmaceuticals, Inc.

$4.23 -$13.25 (-75.80%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$4.25
Day Range
$4.17$4.43
Year Range
$3.95$19.11
Market Cap
354.65M
AVG Volume
2.69M
Trailing/Forward PE
-1.13/-
PEG ratio
0.04
Dividend Yield
-
Next Earnings Date
2026-11-04
Primary Exchange
NASDAQUS
Revenue (USD)
020M40M60M2016201720182019202020212022202320242025
EYPT Revenue (USD) by year
PeriodRevenue (USD)
202531.37M
202443.27M
202346.02M
202241.4M
202136.94M
202034.44M
201920.36M
20184.57M
20172.61M
20166.88M
Net Income (USD)
-300M-200M-100M02016201720182019202020212022202320242025
EYPT Net Income (USD) by year
PeriodNet Income (USD)
2025-231.96M
2024-130.87M
2023-70.8M
2022-102.25M
2021-58.42M
2020-45.39M
2019-56.79M
2018-86.13M
2017-23.02M
2016-18.66M
Operating Income (USD)
-300M-200M-100M02016201720182019202020212022202320242025
EYPT Operating Income (USD) by year
PeriodOperating Income (USD)
2025-243.43M
2024-145.85M
2023-75.07M
2022-99.63M
2021-55.28M
2020-37.29M
2019-47.86M
2018-39.02M
2017-23.11M
2016-18.83M
EBITDA (USD)
-300M-200M-100M02016201720182019202020212022202320242025
EYPT EBITDA (USD) by year
PeriodEBITDA (USD)
2025-220.51M
2024-129.23M
2023-69M
2022-96.62M
2021-50.23M
2020-35.54M
2019-48.01M
2018-81.42M
2017-22.2M
2016-17.95M
Cash Flows (USD)
-300M-200M-100M02016201720182019202020212022202320242025
EYPT Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-243.39M
2024-130.28M
2023-1.61M
2022-67.16M
2021-50.25M
2020-14.8M
2019-56.91M
2018-33.66M
2017-20.33M
2016-20.23M
EPS (USD)
-15-10-502016201720182019202020212022202320242025
EYPT EPS (USD) by year
PeriodEPS (USD)
2025-3.16
2024-2.31
2023-1.85
2022-3.33
2021-2.02
2020-3.55
2019-5.54
2018-13.38
2017-5.9
2016-5.49
Expenses (USD)
0100M200M300MR&DSG&ACapex2016201720182019202020212022202320242025
EYPT Expenses (USD) by year
PeriodExpenses (USD)
2025276.02M
2024189.47M
2023119.94M
2022112.11M
202181.73M
202063.8M
201963.29M
201843.77M
201726.05M
201625.79M
Cash & Debt (USD)
0100M200M300M400MCashLong Term DebtShort Term Debt2016201720182019202020212022202320242025
EYPT Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2025306.09M
2024370.91M
2023331.05M
2022144.56M
2021211.56M
202044.91M
201922.21M
201845.26M
201712.88M
201617.53M
Debt ratios
-0.500.511.520182019202020212022202320242025
EYPT Debt ratios by year
PeriodDebt ratios
20250.55
20241.01
20231.3
20220.43
20210.8
20200.02
2019-0.17
20180.2
Margins
-400%-300%-200%-100%0%100%2016201720182019202020212022202320242025
EYPT Margins by year
PeriodMargins
202593.41%
202491.42%
202389.93%
202279.89%
202177.86%
202083.09%
201986.81%
2018-304.77%
2017-191.03%
2016-104.84%
Return on Capital
-800%-600%-400%-200%0%2016201720182019202020212022202320242025
EYPT Return on Capital by year
PeriodReturn on Capital
2025-75.78%
2024-38.89%
2023-26.58%
2022-106.11%
2021-31.68%
2020-244.83%
2019-681.79%
2018-228.86%
2017-232.42%
2016-126.39%
Shares Outstanding
025M50M75M100M2016201720182019202020212022202320242025
EYPT Shares Outstanding by year
PeriodShares Outstanding
202583.03M
202464.56M
202342.17M
202237.35M
202132.7M
202014.5M
201910.67M
20189.21M
20174.45M
20163.42M
Book Value Per Share (USD)
024682016201720182019202020212022202320242025
EYPT Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20253.69
20245.21
20236.32
20222.58
20215.64
20201.28
20190.78
20184.09
20172.22
20164.32
Total Assets (USD)
0200M400M600M2016201720182019202020212022202320242025
EYPT Total Assets (USD) by year
PeriodTotal Assets (USD)
2025364M
2024418.46M
2023355.18M
2022180.36M
2021263.37M
202091.72M
201972.97M
201878.17M
201714.2M
201619.75M
Employee Count
01002003002016201720182019202020212022202320242025
EYPT Employee Count by year
PeriodEmployee Count
2025214
2024165
2023121
2022144
2021122
202098
201984
201844
201722
201620
Free Cash Flow Yield
-80%-60%-40%-20%0%med -23.49%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
EYPT Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-74.1%
Sep 26-68.44%
Aug 26-69.97%
Aug 26-58.92%
Aug 26-21.25%
Aug 26-22.57%
Jul 26-25.78%
Jul 26-25.9%
Jul 26-23.74%
Jul 26-21.45%
Jul 26-22.59%
Jun 26-23.11%
Jun 26-23.25%
Jun 26-24.23%
Jun 26-26.8%
May 26-23.25%
May 26-24.42%
May 26-25.57%
May 26-23.11%
May 26-21.97%
Apr 26-21.29%
Apr 26-19.63%
Apr 26-20.66%
Apr 26-21.88%
Mar 26-23.45%
Mar 26-22.16%
Mar 26-22.21%
Mar 26-18.61%
Feb 26-17.33%
Feb 26-19.86%
Feb 26-23.52%
Feb 26-22.89%
Jan 26-22.51%
Jan 26-20.05%
Jan 26-20.19%
Jan 26-18.76%
Jan 26-17.41%
Dec 25-16.64%
Dec 25-17.46%
Dec 25-19.04%
Dec 25-17.16%
Nov 25-20.53%
Nov 25-22.25%
Nov 25-26.29%
Nov 25-27.15%
Oct 25-21.2%
Oct 25-23.16%
Oct 25-23.86%
Oct 25-20.45%
Oct 25-20.21%
Sep 25-19.96%
Sep 25-20.94%
Sep 25-20.79%
Sep 25-19.81%
Aug 25-23.98%
Aug 25-23.46%
Aug 25-25.02%
Aug 25-27.13%
Aug 25-22.34%
Jul 25-20.69%
Jul 25-20.81%
Jul 25-20.93%
Jul 25-22.31%
Jun 25-22.5%
Jun 25-25.76%
Jun 25-24.02%
Jun 25-24.26%
May 25-29.96%
May 25-38.18%
May 25-35.38%
May 25-37.33%
May 25-27.64%
Apr 25-31.68%
Apr 25-35.53%
Apr 25-37.51%
Apr 25-43.78%
Mar 25-34.62%
Mar 25-32.29%
Mar 25-30.95%
Mar 25-28.3%
Feb 25-34.57%
Feb 25-35.25%
Feb 25-33.35%
Feb 25-33.35%
Jan 25-28.34%
Jan 25-25.41%
Jan 25-28.98%
Jan 25-25.99%
Jan 25-26.25%
Dec 24-30.11%
Dec 24-30.53%
Dec 24-29.06%
Dec 24-24.89%
Nov 24-24.5%
Nov 24-24.22%
Nov 24-23.64%
Nov 24-18.64%
Nov 24-14.71%
Oct 24-18.67%
Oct 24-16.05%
Price to Sales
0200400600med 17.92Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
EYPT Price to Sales by year
PeriodPrice to Sales
Sep 26131.26
Sep 26142.12
Aug 26139.01
Aug 26165.08
Aug 26457.69
Aug 26431.01
Jul 26138.34
Jul 26137.67
Jul 26150.2
Jul 26166.24
Jul 26157.88
Jun 26154.27
Jun 26153.36
Jun 26147.15
Jun 26133.04
May 26153.36
May 26146.02
May 26139.47
May 26154.27
May 2635.31
Apr 2636.44
Apr 2639.51
Apr 2637.56
Apr 2635.47
Mar 2633.08
Mar 2635.02
Mar 2634.94
Mar 2641.68
Feb 2629.1
Feb 2625.41
Feb 2621.44
Feb 2622.04
Jan 2622.41
Jan 2625.16
Jan 2624.99
Jan 2626.9
Jan 2628.97
Dec 2530.31
Dec 2528.89
Dec 2526.5
Dec 2529.4
Nov 2524.58
Nov 2522.67
Nov 2519.19
Nov 2518.58
Oct 2517.64
Oct 2516.14
Oct 2515.67
Oct 2518.28
Oct 2518.5
Sep 2518.73
Sep 2517.85
Sep 2517.99
Sep 2518.88
Aug 2515.59
Aug 2515.94
Aug 2514.94
Aug 2513.78
Aug 2512.09
Jul 2513.05
Jul 2512.97
Jul 2512.9
Jul 2512.1
Jun 2512
Jun 2510.48
Jun 2511.24
Jun 2511.13
May 259.01
May 257.07
May 257.63
May 257.23
May 2510.89
Apr 259.5
Apr 258.47
Apr 258.03
Apr 256.88
Mar 258.7
Mar 259.32
Mar 259.73
Mar 2510.64
Feb 257.47
Feb 257.33
Feb 257.74
Feb 257.74
Jan 259.11
Jan 2510.16
Jan 258.91
Jan 259.93
Jan 259.84
Dec 248.58
Dec 248.46
Dec 248.89
Dec 2410.37
Nov 2410.54
Nov 2410.66
Nov 2410.92
Nov 2413.85
Nov 2412.73
Oct 2410.03
Oct 2411.67
Price/Operating Cashflow
0200400600800med 69.04Aug 23Sep 23Nov 23Dec 23Feb 24Apr 24May 24
EYPT Price/Operating Cashflow by year
PeriodPrice/Operating Cashflow
May 24250.98
May 24266.28
May 24271.9
May 24443.94
Apr 24376.7
Apr 24396.94
Apr 24504.89
Apr 24456.09
Mar 24464.86
Mar 24500.62
Mar 24483.08
Mar 24548.75
Mar 24629.71
Feb 2482.12
Feb 2487.56
Feb 2489.08
Feb 2488.77
Jan 2481.87
Jan 2469.04
Jan 2470.4
Jan 2463.1
Dec 2371.48
Dec 2369.84
Dec 2360.47
Dec 2359.23
Dec 2320.44
Nov 2318.99
Nov 2320.57
Nov 2319.8
Nov 2323.97
Oct 2315.33
Oct 2319.45
Oct 2321.04
Oct 2322.37
Sep 2320.76
Sep 2321.95
Sep 2327.23
Sep 2326.06
Sep 2327.33
Aug 2329.38
Aug 2337.15
Aug 2336.89
Aug 2333.51
Price to Book
02468med 3.33Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
EYPT Price to Book by year
PeriodPrice to Book
Sep 262.2
Sep 262.38
Aug 262.33
Aug 262.77
Aug 267.67
Aug 267.22
Jul 264.57
Jul 264.55
Jul 264.96
Jul 265.49
Jul 265.22
Jun 265.1
Jun 265.07
Jun 264.86
Jun 264.4
May 265.07
May 264.82
May 264.61
May 265.1
May 263.62
Apr 263.74
Apr 264.05
Apr 263.85
Apr 263.63
Mar 263.39
Mar 263.59
Mar 263.58
Mar 264.27
Feb 266.16
Feb 265.37
Feb 264.54
Feb 264.66
Jan 264.74
Jan 265.32
Jan 265.29
Jan 265.69
Jan 266.13
Dec 256.41
Dec 256.11
Dec 255.6
Dec 256.22
Nov 255.2
Nov 254.8
Nov 254.06
Nov 253.93
Oct 253.72
Oct 253.41
Oct 253.31
Oct 253.86
Oct 253.9
Sep 253.95
Sep 253.77
Sep 253.79
Sep 253.98
Aug 253.29
Aug 253.36
Aug 253.15
Aug 252.91
Aug 252.27
Jul 252.45
Jul 252.44
Jul 252.42
Jul 252.27
Jun 252.25
Jun 251.97
Jun 252.11
Jun 252.09
May 251.69
May 251.33
May 251.43
May 251.36
May 251.4
Apr 251.22
Apr 251.09
Apr 251.03
Apr 250.88
Mar 251.12
Mar 251.2
Mar 251.25
Mar 251.37
Feb 251.56
Feb 251.53
Feb 251.62
Feb 251.62
Jan 251.9
Jan 252.12
Jan 251.86
Jan 252.08
Jan 252.06
Dec 241.79
Dec 241.77
Dec 241.86
Dec 242.17
Nov 242.2
Nov 242.23
Nov 242.28
Nov 242.9
Nov 242.81
Oct 242.21
Oct 242.58
EyePoint Pharmaceuticals, Inc.
EYPT
Stockpicker

Video analysis: EYPT

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: EYPT

EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

globenewswire.com · 10 Sep 2026

EYPT Investigation Alert: EyePoint, Inc. Investors Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

prnewswire.com · 10 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).

EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

seekingalpha.com · 9 Sep 2026

EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

globenewswire.com · 8 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT).

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

gurufocus.com · 6 Sep 2026

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer and Check, LLP PR Newswire

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

prnewswire.com · 6 Sep 2026

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa., Sept. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm

globenewswire.com · 4 Sep 2026

EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm

RADNOR, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

gurufocus.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PR Newswire

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.